Recent News

• 22 January 2026   Press Release

  EMUNO Therapeutics Achieves Research Milestone with Enamine's IDD Platform

  Freiburg, Germany / Frankfurt, Germany / Kyiv, Ukraine / Wroclaw, Poland, 22 January 2026 – EMUNO Therapeutics reached critical R&D milestones with remarkable efficiency in their fight against cancer supported by the competence and Integrated Drug Discovery (IDD) Platform of the CRO Enamine. EMUNO and Enamine entered a comprehensive collaboration in June 2025 to advance EMUNO’s small molecule programs in immuno-oncology aimed at achieving clinical impact for challenging malignancies. EMUNO’s mission is to develop medicines which modulate specific immune responses in a controlled, pathway-specific approach to treat autoimmune disorders or overcome cancer immune evasion, and to enhance human health and wellbeing. The European Union supports their small molecule immune activator program with an EIC Transition Grant from the European Innovation Council. The IMMUNOCON project aims to advance the drug candidate EMT-224 towards clinical readiness to address the urgent need for effective therapies for refractory and treatment-resistant solid tumors, commonly seen in advanced/ late-stage cancer patients.

• 16 January 2026   Press Release

  Enamine's IDD Platform Boosts ABX-CRO's Translational Medicine Approach towards Imaging Agents and Radiopharmaceuticals

  Dresden, Germany / Frankfurt, Germany / Kyiv, Ukraine / Wroclaw, Poland, 16 January 2026 – ABX-CRO and Enamine initiated their cooperation in 2024. Since then, Enamine supports ABX-CRO with its integrated competencies in biology, chemistry, and computational sciences through its research centers in Frankfurt/Germany, Kyiv/Ukraine, and Wroclaw/Poland. The initial relationship proved to be highly productive, securing innovation in short research cycles and utilizing resources at its highest return on investment. In consequence of this success, ABX-CRO and Enamine continue to deepen their relationship for the future.

• 02 December 2025   Press Release

  Peapod Bio Inc. and Enamine Ltd. Announce Strategic Collaboration

  CHICAGO, Peapod Bio Inc., a leader in innovative assay development and high-throughput screening (HTS) solutions, today announced a strategic collaboration with Enamine, a global supplier of high-quality small molecule libraries. This partnership enables Peapod Bio to offer its clients fully integrated screening campaigns with access to Enamine’s world-class compound collections nearing five million compounds, accelerating hit discovery.